相关实验视频
Updated: Jul 21, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
使用FHIR资源对糖尿病患者需求的概况
Ylenia Murgia1, Christian Esposito2, Roberta Gazzarata3,4,5
1Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genoa, Genoa, Italy.
Studies in health technology and informatics
|May 17, 2025
概括
这项研究使用数字健康解决方案在社区医学中标准化了2型糖尿病管理的数据. 它增强了医疗保健系统的互操作性和数据集成.
科学领域:
- 数字健康数字健康
- 医疗信息学 医疗信息学
- 糖尿病管理 糖尿病管理
背景情况:
- 社区医学需要改进的数字技术,以更好地照顾患者.
- 健康数据的标准化和互操作性对于有效的慢性疾病管理至关重要.
- 意大利的"社区医学的数字健康解决方案" (DHEAL-COM) 项目解决了这些需求.
研究的目的:
- 在社区医学中确定和结构化2型糖尿病管理的关键数据要求.
- 利用数字健康解决方案,提高患者数据的标准化和互操作性.
- 为了使数据要求与意大利医疗保健法规和国际标准保持一致.
主要方法:
- 定义了四个核心数据域:患者详细信息,病史,生活方式和健康监测.
- 使用健康水平七 (HL7) 快速医疗互操作性资源 (FHIR) 发布4 (r4) 用于数据映射.
- 综合逻辑观测标识符名称和代码 (LOINC) 以提高数据映射质量和一致性.
主要成果:
- 成功构建了全面2型糖尿病护理的基本数据要求.
- 使用HL7 FHIR r4资源 (例如患者,观察,情况) 映射数据需求.
- 展示了一种方法来提高数据的互操作性和跨多种健康系统的整合.
结论:
- 建议使用HL7 FHIR r4和LOINC代码进行数据结构和映射方法,提高了社区医学中数字健康解决方案的互操作性.
- 这种方法为在糖尿病护理中无交换数据和整合提供了基础.
- 未来的工作包括制定实施指南,并将该方法应用于其他慢性疾病.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...